Provided by Tiger Trade Technology Pte. Ltd.

Galectin Therapeutics

3.88
+0.20005.43%
Post-market: 3.88-0.0008-0.02%18:27 EDT
Volume:227.66K
Turnover:873.36K
Market Cap:391.88M
PE:-9.02
High:3.97
Open:3.68
Low:3.58
Close:3.68
52wk High:7.13
52wk Low:2.03
Shares:101.00M
Float Shares:48.17M
Volume Ratio:0.78
T/O Rate:0.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4302
EPS(LYR):-0.4847
ROE:-3727.94%
ROA:-64.18%
PB:-2.82
PE(LYR):-8.00

Loading ...

Galectin Therapeutics reports Hepatology publication of NAVIGATE Phase 2b belapectin data

Reuters
·
May 11

Galectin Therapeutics Announces Publication of Navigate Phase 2B Trial Results for Belapectin in the Journal of Hepatology

THOMSON REUTERS
·
May 11

Galectin Therapeutics posts belapectin MASH cirrhosis, portal hypertension KOL presentation

Reuters
·
Apr 28

Galectin Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Apr 02

Galectin net loss narrows 34.4% to $31M in FY25

Reuters
·
Apr 01

Galectin Therapeutics Files $200 Million Mixed Shelf

MT Newswires Live
·
Apr 01

Galectin Therapeutics Inc - May Offer up to $200 Mln of Common Stock, Warrants, and Rights - SEC Filing

THOMSON REUTERS
·
Apr 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Terns Pharmaceuticals (TERN), Sangamo Therapeutics (SGMO) and Galectin Therapeutics (GALT)

TIPRANKS
·
Mar 31

Galectin Therapeutics Q4 EPS $(0.08) Beats $(0.11) Estimate

Benzinga Earnings
·
Mar 31

Liver drug developer Galectin Therapeutics' 2025 net loss narrows on reduced R&D costs

Reuters
·
Mar 31

Galectin Therapeutics FY EPS USD -0.48

THOMSON REUTERS
·
Mar 31

Galectin Therapeutics Inc - FY2025 Net Loss Applicable to Common Stockholders Was $31.0 Mln, or ($0.48) per Share

THOMSON REUTERS
·
Mar 31

Press Release: Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update

Dow Jones
·
Mar 31

Top News Today/Canada: Government Records C$5.07 Billion Budget Deficit

Dow Jones
·
Mar 28

Galectin Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview

Reuters
·
Mar 27

Galectin Therapeutics Strengthens Board of Directors With Appointment of Henry Brem, M.d.

THOMSON REUTERS
·
Mar 17

Galectin Therapeutics appoints Henry Brem to board as independent director

Reuters
·
Mar 17

Compelling Risk‑Reward in Galectin Therapeutics: Belapectin’s Differentiated Profile and Biomarker Data Support Buy Rating

TIPRANKS
·
Mar 11

Galectin Therapeutics to Host Virtual KOL Event on Belapectin Development Program for MASH Cirrhosis and Portal Hypertension

Reuters
·
Feb 27